DOXORUBICIN , CYCLOPHOSPHAMIDE , RITUXIMAB , POLATUZUMAB VEDOTIN , PREDNISONE , -, Zilovertamab vedotin
MK-2140-011
Phase 2 small_molecule active
Quick answer
DOXORUBICIN , CYCLOPHOSPHAMIDE , RITUXIMAB , POLATUZUMAB VEDOTIN , PREDNISONE , -, Zilovertamab vedotin for Diffuse Large B-Cell Lymphoma (DLBCL) is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active